Aquestive Therapeutics, Inc. (NASDAQ: AQST) director Richard J. Daly has disclosed a purchase of company shares, according to a regulatory filing. The transactions, executed on November 10, 2026, carried a total value of approximately $99,330.
Daly acquired 28,025 shares of Aquestive's common stock through open-market transactions. The purchases were split between two price points: 1,200 shares at $3.53 each and an additional 26,825 shares at $3.545 per share. Following the transactions, Daly directly owns 28,025 shares of the company's common stock.
The insider purchase arrives as Aquestive shares change hands at $3.60. The stock has declined 44.6% year-to-date and sits well below its 52-week high of $6.74. According to one analysis, the stock appears overvalued at current levels. Analysts, however, remain optimistic, with price targets spanning $6 to $11.
In other recent developments, Aquestive Therapeutics reported financial results for the third quarter of 2026 that fell short of Wall Street expectations. The company posted an adjusted loss of $0.18 per share, while analysts had projected a loss of $0.12 per share. Revenue for the quarter totaled $7.5 million, missing the anticipated $11.02 million.
Despite the financial shortfall, Aquestive Therapeutics continues to advance its lead drug candidate toward a key FDA decision. The company also stated that it expects to conclude the year with more than $70 million in cash. These developments are significant as they could impact future financial performance. Investors should note that the company continues to focus on its drug development pipeline despite the revenue and earnings miss. The financial community will be watching closely for any updates on the FDA decision regarding the lead drug candidate.
The disclosed purchase by Daly represents a direct acquisition of shares in the open market. Such transactions by directors are typically monitored for signals about internal views on valuation and prospects, though the filing itself does not include any statement of intent or outlook from the director.
Aquestive's recent quarterly results and its pipeline progress present a mixed picture. The revenue and earnings miss underscore the challenges the company faces in meeting analyst expectations, while the expected cash balance of more than $70 million provides a measure of financial runway. The pending FDA decision on the lead drug candidate is a key event that could influence the company's trajectory.
Analyst price targets between $6 and $11 suggest a range of views on the stock's potential, contrasting with the current trading level of $3.60 and the overvaluation assessment from one analysis. The year-to-date decline of 44.6% and the distance from the 52-week high of $6.74 reflect the stock's recent performance.
Investors and analysts will continue to track insider transactions, quarterly financial results, and regulatory milestones as they assess Aquestive Therapeutics' outlook.